Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuro-Cells
- Development stage
- Phase 3
- Lead developer
- Neuroplast
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Neuro-Cells is an autologous fresh stem cell-containing product developed by Neuroplast. It is designed to treat traumatic spinal cord injury (TSCI) by modulating secondary inflammation, reducing apoptosis (cell death) in the injured spinal cord, decreasing scar tissue formation, and fostering a cell regenerative environment within the damaged spinal cord.
- Brand names
- Neuro-Cells
- Other names
- autologous somatic cell therapy
Beyond the preview
Go deeper on Neuro-Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuro-Cells.